Investment area

Seed Investments



Date of investment

October 2018

Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.

Visit site


Morten Graugaard Døssing


Department: Seed Investments

Morten joined Novo Holdings in 2016 and serves as Partner in the company creation team of Seed Investments where he leads new company formation. He serves on the Board of Acesion Pharma, Avilex, Camels IDS, Hoba Therapeutics, NMD Pharma, STipe Therapeutics, and Syndesi Therapeutics.

Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting.

Morten holds an MSc in Human Biology from the University of Copenhagen.